B.V. Patel Pharmaceutical Education Research & Development (PERD) centre, India
Priti Desai has completed her Ph.D. at the age of 30 years from Bhavnagar University and postdoctoral studies from NIPER-Ahmedabad. She is the Scientist-B in a premier Pharmaceutical Science organization. She has awarded DBT scholarship for post-doctoral studies in NIPER, Ahmedabad. She has independant project on vaccine development against shigellosis which is funded by Central Government Agencies (ICMR). She has a publication in peer reviewd journal like Biotechnology Advances.
Shigellosis is an acute invasive disease of the lower intestine which affl icts millions of people worldwide with an estimated one million fatalities per annum. Among the 50 serotypes and subtypes of Shigella, SD1 is the most virulent type and responsible for epidemics and pandemics. In the last decade, antibiotic resistant SD1 strains have been isolated with increasing frequency in Africa and Asia which reduce the option of eff ective oral therapy. Th e magnitude of the public health threat, development of vaccine against Shigella is considered a public health priority. Th ere is no approved Shigella vaccine in the market though attempts have been made to develop an eff ective vaccine against shigellosis using killed, attenuated and subunit vaccine approach. Th e purpose of the study is to develop an oral vaccine against SD1 using genetically engineered Lactocoocus lactis expressing SD1 antigens to provide mucosal immunity. L. lactis, being pro-biotic bacteria has been the cynosure of novel vaccine-development platform because of its safety, stability in the stomach, and immunomodulatory properties. In this study, using bioinformatic tools and available literatures, we identifi ed genes OmpA, OspC2 and StxB as a probable vaccine candidates. OmpA and OspC2 were successfully cloned in to L. lactis expression vectors and their presence were confi rmed by PCR and RE digestion tests. Aft er confi rmation, L. lactis NZ9000 was successfully transformed with the constructed vectors pSEC:OmpA and pSEC:OspC2. Expressed antigens were confi rmed by gene specifi c PCR and Western blotting. Th e effi cacy of these expressed antigens to generate the serum and mucosal specifi c antibodies in the experimental animals is underway.